ACE Report Cover
Electrochemical versus plasma-coated femoral implant in total hip arthroplasty
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Language
Download Download Download
Download
Cite this Report Cite this Report Cite this Report
Cite
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Favorites
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Language
Download Download Download
Download
Cite this Report Cite this Report Cite this Report
Cite
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Favorites
ARTHROPLASTY
Electrochemical versus plasma-coated femoral implant in total hip arthroplasty .
Verified
This report has been verified by one or more authors of the original publication.

OrthoEvidence Journal (OE Journal) - ACE Report

OE Journal. 2013;1(12):47 Acta Orthop. 2011 Feb;82(1):13-9

50 patients undergoing total hip arthroplasty were randomized to receive either plasma-sprayed hydroxyapatite (HA) or electrochemically deposited hydroxyapatite (Bonemaster, BM),as a coating for the fixation of uncemented femoral stems, in order to compare the safety and efficacy of the two coatings. At a follow-up of two years, the two groups were similar in regards to their clinical outcomes.


Publication Funding Details +
Funding:
Industry funded
Sponsor:
Biomet Europe
Conflicts:
None disclosed

Risk of Bias

6/10

Reporting Criteria

17/20

Fragility Index

N/A

Was the allocation sequence adequately generated?

Was allocation adequately concealed?

Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?

Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?

Blinding Patients: Was knowledge of the allocated interventions adequately prevented?

Was loss to follow-up (missing outcome data) infrequent?

Are reports of the study free of suggestion of selective outcome reporting?

Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?

Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?

Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?

Yes = 1

Uncertain = 0.5

Not Relevant = 0

No = 0

The Reporting Criteria Assessment evaluates the transparency with which authors report the methodological and trial characteristics of the trial within the publication. The assessment is divided into five categories which are presented below.

2/4

Randomization

3/4

Outcome Measurements

4/4

Inclusion / Exclusion

4/4

Therapy Description

4/4

Statistics

Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65

The Fragility Index is a tool that aids in the interpretation of significant findings, providing a measure of strength for a result. The Fragility Index represents the number of consecutive events that need to be added to a dichotomous outcome to make the finding no longer significant. A small number represents a weaker finding and a large number represents a stronger finding.

Why was this study needed now?

Alternative bone coatings, such as Bonemaster (BM), provide potential advantages in terms of remodelling and transporting of bone-active substances. The trial was necessary to investigate whether the use of this alternative is safe for conventional clinical use.

What was the principal research question?

In patients undergoing total hip arthroplasty for non-inflammatory osteoarthritis, does electrochemically deposited Bonemaster provide non-inferior results in terms of safety, as compared with a conventional femoral implant utilizing plasma-sprayed hydroxyapatite?

Study Characteristics +
Population:
50 patients (55 hips) with non-inflammatory osteoarthritis (end-stage) of the hip
Intervention:
Intervention group received a 28-mm cobalt-chrome modular head coated with Bonemaster using electrochemical deposition (n=31)
Comparison:
Control group received a conventional 28-mm cobalt-chrome modular head with plasma-sprayed hydroxyapatite (n=24)
Outcomes:
Bone mineral density (BMD), Femoral stem migration (RSA), Harris Hip Score, Oxford Hip Score
Methods:
RCT; Multicenter
Time:
2 years post-operative
What were the important findings?
  • The null hypothesis was rejected for BMD in Gruen zone 1 (p = .01); bone loss was less in the BM group. The null hypothesis was accepted for all other regions (p > .05)
  • No statistically significant results were obtained with respect to femoral migration or rotation following implantation (p > .05)
  • There were no significant differences in the Harris Hip Scores at two year follow-up between the groups (p > .05)
  • There were no significant differences in the oxford hip score between the two groups (p > .05)
What should I remember most?

Functional scores, migration, and rotation of the femoral head following total hip arthroplasty were not significantly different. Potential benefits in terms of bone mineral density were identified in favor of the Bonemaster group.

How will this affect the care of my patients?

The results suggest that Bonemaster is clinically non-inferior to conventional plasma-sprayed hydroxyapatite and is a viable alternative. Long term follow-up is necessary to investigate other potential benefits of electrochemical deposition and whether or not long-term fixation is achieved. The small sample size of the study should be taken into account.

DISCLAIMER

This content found on this page is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. If you require medical treatment, always seek the advice of your physician or go to your nearest emergency department. The opinions, beliefs, and viewpoints expressed by the individuals on the content found on this page do not reflect the opinions, beliefs, and viewpoints of OrthoEvidence.

0 of 4 monthly FREE articles unlocked
You've reached your limit of 4 free articles views this month

Access to OrthoEvidence for as little as $1.99 per week.

Stay connected with latest evidence. Cancel at any time.
  • Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
  • Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
  • Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Upgrade
Welcome Back!
Forgot Password?
Start your FREE trial today!

Your account will be affiliated with
and includes free access to OrthoEvidence


OR
Forgot Password?

OR
Please check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see an email, please check your spam or junk folder.

For further assistance, contact our support team.

Please login to enable this feature

To access this feature, you must be logged into an active OrthoEvidence account. Please log in or create a FREE trial account.

Translate ACE Report

OrthoEvidence utilizes a third-party translation service to make content accessible in multiple languages. Please note that while every effort is made to ensure accuracy, translations may not always be perfect.

How to cite this ACE Report

OrthoEvidence. Electrochemical versus plasma-coated femoral implant in total hip arthroplasty. OE Journal. 2013;1(12):47. Available from: https://myorthoevidence.com/AceReport/Show/electrochemical-versus-plasma-coated-femoral-implant-in-total-hip-arthroplasty

Copy Citation
Please login to enable this feature

To access this feature, you must be logged into an active OrthoEvidence account. Please log in or create a FREE trial account.

Premium Member Feature

To access this feature, you must be logged into a premium OrthoEvidence account.

Share this ACE Report